Arvest Bank Trust Division Invests $21.08 Million in IQVIA Holdings Inc. (NYSE:IQV)

Arvest Bank Trust Division acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 88,953 shares of the medical research company's stock, valued at approximately $21,079,000. IQVIA accounts for about 1.2% of Arvest Bank Trust Division's portfolio, making the stock its 26th largest holding.

Several other hedge funds and other institutional investors have also recently modified their holdings of IQV. Capital Performance Advisors LLP purchased a new position in IQVIA during the third quarter valued at approximately $27,000. Park Place Capital Corp bought a new stake in shares of IQVIA during the 3rd quarter valued at $28,000. Itau Unibanco Holding S.A. purchased a new position in shares of IQVIA during the 2nd quarter valued at $29,000. International Assets Investment Management LLC bought a new position in IQVIA in the 2nd quarter worth $32,000. Finally, Avior Wealth Management LLC increased its stake in IQVIA by 117.6% in the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock worth $38,000 after buying an additional 87 shares in the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. StockNews.com lowered IQVIA from a "buy" rating to a "hold" rating in a research note on Thursday, November 28th. JPMorgan Chase & Co. dropped their price target on IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a research note on Tuesday, November 5th. Royal Bank of Canada reiterated an "outperform" rating and set a $270.00 price objective on shares of IQVIA in a research report on Wednesday. BTIG Research dropped their target price on shares of IQVIA from $290.00 to $260.00 and set a "buy" rating for the company in a research report on Friday, November 1st. Finally, Morgan Stanley cut their target price on shares of IQVIA from $280.00 to $265.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and an average target price of $257.60.

IQVIA Trading Down 0.3 %

Shares of NYSE IQV traded down $0.70 during trading hours on Thursday, hitting $200.37. 1,143,937 shares of the company traded hands, compared to its average volume of 1,186,217. The stock has a market capitalization of $36.37 billion, a price-to-earnings ratio of 26.29, a price-to-earnings-growth ratio of 2.08 and a beta of 1.49. The company's 50 day moving average price is $213.40 and its 200 day moving average price is $224.61. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.